Anticancer Agent Reduces Complications After Stem-Cell Transplant

Published January 6, 2013

Anticancer agent reduces complications after stem-cell transplant

Filed under: drug rehab centers in michigan

Vorinostat, a drug already approved by the FDA for the treatment of cutaneous T-cell lymphoma, has been found to reduce the risk of graft-versus-host disease (GVHD) in persons undergoing allogeneic hematopoietic stem-cell transplantation. … “[GVHD …
Read more on Oncology Nurse Advisor